Abstract
AbstractAntibody dynamics on membranes, such as endocytosis and clustering, are vital in determining antibody functions. In this study, we demonstrated that glycan conjugation can modulate antibody dynamics through the glycan–lectin interaction to regulate its potency. The anti‐HER2 antibody, an anti‐breast‐cancer antibody, was conjugated with galactose‐containing N‐glycan, and its internalization was suppressed by interaction with galectin‐3, leading to enhanced complement‐dependent cytotoxic (CDC) activity. This glycan–antibody conjugate is proposed as a new approach to modulate antibody activity and may provide an alternative strategy for redeveloping antibody drugs that do not exhibit sufficient activity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
